Manipal Hospitals to Acquire Sahyadri for ₹6,400 Cr in Major Healthcare Deal

New Delhi — In a major development in India’s private healthcare landscape, Manipal Hospitals has sought approval from the Competition Commission of India (CCI) to acquire Sahyadri Hospitals, a leading Western India-based hospital chain, for a reported ₹6,400 crore.

This strategic move is expected to bolster Manipal’s footprint in Maharashtra and consolidate its position as one of the top three hospital networks in the country by bed capacity and revenue.

🏥 Sahyadri’s Presence:

Sahyadri Hospitals operates nine multi-speciality hospitals across cities like Pune, Nashik, and Karad, with a total bed strength of over 900 beds. The chain is known for its strong clinical specialties in oncology, neurology, cardiology, and organ transplants.

💼 Strategic Push by Manipal:

Manipal Hospitals, backed by global investment firm TPG Capital, has been actively expanding. The group previously acquired Columbia Asia and Vikram Hospital, building one of India’s largest integrated health networks.

This latest deal signals continued consolidation in India’s private healthcare market, driven by the rising demand for quality tertiary care, operational synergies, and access to underserved regional hubs.

🔍 What Comes Next:

The acquisition plan now awaits CCI’s approval, which is a mandatory regulatory step to ensure compliance with India’s antitrust laws. If cleared, the integration is likely to enhance patient access to Manipal’s standardised protocols, advanced medical tech, and streamlined care delivery across Western India.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March